BoomRay and Novartis sign $900m deal for radioligand therapy
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand …
Post
-
-
Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal
Boehringer Ingelheim and Envisagenics have entered a research collaboration and option agreement that aims to validate tumour-specific targets for the …
-
Why Most FDA Warning Letters Share a Single — and Fixable — Root Cause
When a warning letter from the U.S. Food and Drug Administration (FDA) lands on a quality leader's desk, the instinct …
-
Novo targets blockbuster-heavy 2030 but share slump signals unease
Shares in Novo have slumped despite the drugmaker outlining a five-year commercial strategy in a bid to return to winning …
-
What drives time-to-randomization in oncology trials?
In the United States, an estimated 2,041,910 new cases of cancer were diagnosed in 2025, with 618,120 people dying from …
-
Novo targets blockbuster-heavy 2030 but share slump signals unease
Shares in Novo have slumped despite the drugmaker outlining a five-year commercial strategy in a bid to return to winning …
-
What drives time-to-randomization in oncology trials?
In the United States, an estimated 2,041,910 new cases of cancer were diagnosed in 2025, with 618,120 people dying from …
-
Made Scientific acquires cell therapy facility in Pennsylvania, US
Made Scientific has acquired an 85,000ft² cell therapy manufacturing facility in Pennsylvania, US, from National Resilience, adding an operational site …
-
EC approves Menarini and NewAmsterdam’s obicetrapib therapies
The European Commission (EC) has granted marketing authorisation to NewAmsterdam Pharma and Menarini Group for Ubeslo (obicetrapib 10mg monotherapy) and …
-
Beijing unveils blueprint for biomedical dominance by 2030
The Chinese government has unveiled an ambitious five-year plan for its biomedical industry, as the country looks to cement its …
-
Telix to acquire ITM in deal worth up to $2.35bn
Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn. The deal …
-
How DFE Pharma supports confident continuous manufacturing decisions
For pharmaceutical manufacturers, the question is whether a specific formulation can perform consistently under continuous conditions. That requires evidence on …
-
Sandoz and mAbxience agree on emicizumab biosimilar partnership
Sandoz and mAbxience have signed a licensing, development, manufacturing and commercialisation agreement covering a proposed emicizumab biosimilar candidate for haemophilia …
-
FDA hearing: psychedelics launch needs balanced regulation without limiting access
The area of psychedelic therapeutics has been rapidly growing in research and drug development with the advent of classical psychedelics …
-
FDA approves first gene therapy for Sanfilippo syndrome type A
The US Food and Drug Administration (FDA) has approved Ultragenyx’s gene therapy for Sanfilippo syndrome type A, marking the first …
